Introduction
Chronic graft-versus-host disease (cGVHD) after allogeneic BMT remains a major problem and is associated with significant morbidity and mortality. 1 The gastrointestinal tract is one of the prominent target organs involved in acute and cGVHD. Clinical manifestations include anorexia, nausea and protein-losing enteropathy. Gastrointestinal manifestations can significantly influence the quality of life of patients through impairment of the oral intake, leading to malnutrition and increased morbidity. 2 A group of investigators from France reported the clinical, histological and immunohistochemical features of cGVHD with intestinal involvement in children and demonstrated a dismal outcome with complete recovery in only 58.8% of cases, and death related to chronic GVHD in 17.6% of cases. 3 Histologically, mononuclear cell infiltrates in lamina propria, shortening of villi, mucosal architectural (crypt) distortion and hyperplasia are observed. In severe cases, hyalinization of small venules and subserosal fibrosis/ scarring are described. [3] [4] [5] [6] Although acute GVHD is associated with apoptotic epithelial cells, crypt abscesses and mucosal destruction as major diagnostic criteria, there is no established role of endoscopic evaluation and mucosal biopsy in the diagnosis of gastrointestinal cGVHD besides esophageal manifestations, and histology may remain negative despite clinical evidence of cGVHD. 7 This is possibly due to the fact that the histological changes of chronic gastrointestinal GVHD, such as fibrosis, mononuclear cell infiltration and sclerosis, are mainly confined to submucosa and subserosa, which may be missed by small or superficial biopsies. 6 Treatment of cGVHD requires intensification of immunosuppression over prolonged periods of times. This protracted therapy causes significant side effects such as immunodeficiency, diabetes mellitus, renal insufficiency and osteoporosis and potentially increases morbidity and mortality due to infections. Topical treatment options such as psoralen plus ultraviolet light A and steroids have been successfully used for the treatment of oral and cutaneous manifestations of cGVHD. 8, 9 In the presence of isolated gastrointestinal manifestation, topical treatment with steroids may be a treatment option with local efficacy, free of the unwanted systemic side effects of systemic immunosuppression.
Budesonide (BUD) is a highly potent steroid with a low systemic bioavailability when absorbed through mucosal surfaces, which provides effective local immunosuppression.
In addition to high local anti-inflammatory activity, BUD displays no classical side effects of systemic steroid therapy, due to extensive hepatic first-pass metabolism, converting BUD predominantly to 6b-hydroxy-budesonide and 16a-hydroxy-prednisolone. This reduces the glucocorticoid activity of the parent compound to about a hundredth. Beside other applications (such as in collagenous colitis), BUD has been successfully used in the topical treatment of oral manifestations of cGVHD as well as in the treatment of gastrointestinal manifestations of acute GVHD, but its effectiveness in gastrointestinal cGVHD has not been assessed to date. 10, 11 Moreover, topical beclomethasone dipropionate has been demonstrated to be active in the treatment of the gastrointestinal manifestations of acute GVHD. 12, 13 Here, we present the results of a retrospective evaluation of the efficacy of BUD in 13 patients who received BUD for the treatment of mild or moderate predominantly gastrointestinal manifestations of cGVHD.
Patients and methods
Thirteen patients with a median age of 47 years (21-65) who received BUD for gastrointestinal cGVHD after allogeneic hematopoietic SCT for hematological malignancies between 2000 and 2007 were evaluated for response. Patient characteristics are shown in Table 1 . The conditioning regimen was toxicity-reduced myeloablative (n ¼ 11) or standard myeloablative (n ¼ 2). All patients receiving hematopoetic stem cells from unrelated donors (n ¼ 10) received antithymocyte globulin (ATG) as part of the conditioning regimen. Four patients developed GVHD after donor lymphocyte infusions. GVHD prophylaxis consisted of CYA and MTX (n ¼ 9), CYA and mycophenolate mofetil (MMF) (n ¼ 3) or CYA alone (n ¼ 1). Previous acute GVHD grade 2-3 occurred in seven patients, which was steroid sensitive in six patients, while patient UPN 277 required additional etanercept and daclizumab for the treatment of acute GVHD. 16 Previous mixed acute/chronic GVHD was diagnosed in one patient. One patient had previous acute GVHD grade 1, which remained untreated, and four patients had de novo-onset cGVHD. The median onset of cGVHD occurred on day 217 after transplantation (day 99-420). Four patients had platelets o100 Â 10 9 /l at the onset of cGVHD, and none of the patients had progressive onset of cGVHD. Chronic GVHD was diagnosed and staged according to the NIH criteria for staging and diagnosis of cGVHD. 17 Diagnosis was confirmed by histology (skin n ¼ 1, duodenum/stomach n ¼ 6, oral mucosa n ¼ 1); however, three patients (UPN 558, 627, 667) had negative histology despite typical symptoms of gastrointestinal involvement by cGVHD. Endoscopy with biopsies was performed directly before the start of BUD treatment in patients UPN 582, 566, 630, 627, 585, 558 and 667. Patients UPN 593, 597, 277 and 548 had previous histological confirmation of cGVHD and received BUD in the presence of typical symptoms of gastrointestinal manifestation of cGVHD. Patient UPN 627 had isolated gastrointestinal symptoms and associated eosinophilia before starting BUD treatment, with significant weight loss that relapsed after stopping concomitant CYA.
This made the diagnosis of cGVHD very likely, as other causes of nausea had been excluded. Patient UPN 558 had progressive hyperpigmentation, nausea, mild diarrhea and concomitant rapid complete response of relapsed refractory multiple myeloma after donor lymphocyte infusions at the time of onset of BUD treatment. As he later developed bronchiolitis obliterans, a diagnosis of cGVHD is very likely. Patient UPN 667 developed autoimmune thrombocytopenic purpura shortly after initiation of BUD as well as subsequent cGVHD of the skin with lichenoid morphology and progressive sicca symptoms of the eyes, supporting the initial diagnosis of cGVHD. In two patients (UPN 604 and 631), cGVHD was diagnosed exclusively clinically. Patient UPN 604 had skin manifestations with lichen planus-like morphology, which is diagnostic of cGVHD, whereas patient UPN 631 had no diagnostic features at the time of initiation of BUD, but developed subsequent moderate bronchiolitis obliterans. All but three patients were clinically staged according to NIH consensus criteria. 17 Three patients were retrospectively staged by chart review due to initiation of BUD before the NIH consensus conference. Results of histology were categorized according to the NIH consensus. 7 Five patients had isolated gastrointestinal cGVHD and eight patients had mild multiorgan involvement, including gastrointestinal (n ¼ 7), skin (n ¼ 4), lung (n ¼ 1), oral mucosa (n ¼ 1), and liver (n ¼ 5) manifestations. One patient (UPN 234) had isolated liver manifestations of cGVHD and received BUD due to a high risk of infectious complications due to incompliance. Five patients received treatment with BUD due to isolated gastrointestinal manifestations, whereas patients UPN 604, 566 and 558 received BUD due to risk of relapse of their underlying malignancy. Patients UPN 585 and 597 received BUD because of a high risk of infectious complications with systemic steroids. Patient UPN 277 received BUD due to uncontrolled diabetes with systemic steroids. Patient UPN 427 initially refused systemic steroids in the presence of dominating gastrointestinal manifestations of cGVHD.
While four patients received BUD as second-line single-agent treatment, nine patients received BUD as first-line single-agent treatment of cGVHD. Eight patients received CYA for either prophylaxis of GVHD (n ¼ 5) or treatment of cGVHD (n ¼ 3) before treatment with BUD, and one patient was treated with tacrolimus and prednisolone before treatment with BUD, which were discontinued at the start of BUD. No additional immunosuppressive treatment was started at the onset of treatment with BUD. Six patients continued with CYA through treatment with BUD.
Treatment consisted of BUD at an initial dose of 3 Â 3 mg/day orally. Patient UPN 277 received Entocort (AstraZeneca, Wedel, Germany), whereas all other patients received Budenofalk (Falk Pharma, Freiburg, Germany). BUD was started at a median of day 238 (99-568) after transplantation. Duration of treatment with BUD was median 157 days (29-708) in 10 patients, whereas 3 patients are still undergoing treatment with BUD. All patients were similarly provided with the supportive care standard at the time of their treatment. This included prophylactic antimicrobial cover for pneumocystis carinii with either Bactrim or Atovaquone. Complete remission was defined as complete resolution of all symptoms of cGVHD, whereas partial remission was defined as a reduction in symptoms 450% or resolution of symptoms in one organ and no progression to manifestations at other sites.
Results

Response
Seven patients achieved complete remission of cGVHD on treatment with BUD. One more patient (UPN 566) achieved complete resolution of symptoms of gastrointestinal cGVHD, whereas other manifestations of cGVHD showed no response. One more patient (UPN 667) achieved complete remission of gastrointestinal cGVHD but developed autoimmune thrombocytopenic purpura 2 weeks after initiation of treatment with BUD. Patients who had weight loss earlier gained weight back to baseline after remission of cGVHD. Partial remission of cGVHD was achieved in one patient (UPN 597) with persisting mild cutaneous cGVHD. Three patients (UPN 631, 548 and 558), including the patient who received BUD for treatment of cGVHD of the liver (UPN 631), did not respond to BUD and required subsequent systemic treatment including steroids. Eosinophilia present at the onset of BUD treatment (patients UPN 566 and 667) resolved during the first 2 weeks of treatment in association with response to BUD. Progressive eosinophilia after the start of BUD was observed in patients UPN 548 and 631, who failed treatment with BUD, whereas patients UPN 585, 566, 593 and 630 developed eosinophilia after dose reduction of BUD, associated with reappearance of symptoms of cGVHD. In addition to a response of gastrointestinal cGVHD, improvement was observed in liver manifestations (n ¼ 3), lung (n ¼ 1), skin (n ¼ 2) and eyes (n ¼ 2). Responses were achieved during the first 4 weeks of treatment with BUD. Detailed results are shown in Table 2 .
Follow-up
Ten patients are currently alive, with a median follow-up of 796 days (533-2458) after allogenic hematopoietic SCT and a median follow-up of 506 days after the start of BUD. Two patients died due to invasive mycosis unrelated to BUD, and one patient died due to relapsed AML. Three patients (UPN 630, 558 and 277) are currently being treated for relapse of their underlying malignancy. Three patients (UPN 604, 593 and 630) are still receiving BUD in remission of cGVHD. Patient UPN 667 developed immune thrombocytopenia shortly after remission of gastrointestinal cGVHD, which responded to systemic prednisolone. Four patients (UPN 277, 627, 566 and 585) progressed with cGVHD after dose reduction of BUD and required systemic immunosuppression including steroids. Patients not responding to BUD (UPN 631, 548 and 558) required systemic treatment including steroids.
Side effects
Two patients developed mild systemic side effects of steroids in association with response of cGVHD at other sites (patients UPN 604 and 566). Of note, the side effects were solely observed in patients with a low body weight (o55 kg), indicating a relative overdosage of BUD. No other side effects directly attributable to BUD were observed. Patient UPN 593 required temporary hospitalization with local viral enteritis in complete remission of cGVHD. Patient UPN 585 was temporarily hospitalized due to candida septicemia with a highly resistant strain of candida glabrata acquired before the onset of treatment with BUD. Patient UPN 630 developed bacterial pneumonia during treatment of localized CNS relapse of ALL. Patient UPN 597 developed lethal pulmonary mycosis due to long-term neutropenia after allogenic hematopoietic SCT for advanced myelofibrosis and patient UPN 558 was hospitalized due to bacterial pneumonia after failure of BUD in association with progression of cGVHD. Patient 631 was hospitalized due to bacterial pneumonia during treatment with BUD. Patients 585 and 558 had temporary Clostridium difficile infection in association with antibiotic treatment, which resolved on metronidazole.
Discussion
Systemic steroids have been proven to be the most effective immunosuppressive agent for the treatment of cGVHD. 18 Intensification and/or long-term use of systemic immunosuppression with steroids is associated with severe side effects such as the induction of diabetes mellitus, myopathy, osteoporosis and increased susceptibility to infections. Moreover, systemic steroids may interfere with the graft-versus-malignancy effect. Therefore, topical steroids may be of use in situations where the side effects of systemic steroids need to be avoided (increased frequency of infectious complications or presence of uncontrolled diabetes mellitus) or after transplantation when there is a high risk of relapse of underlying malignancy.
The high response rate of gastrointestinal manifestations of cGVHD indicates that BUD represents a treatment option in mild-to-moderate gastrointestinal cGVHD especially in situations where there is either a high risk of systemic steroid toxicity or a high risk of relapse of malignant disease. Furthermore, systemic responses have been observed, which may be partly explained by the high steroid receptor affinity of BUD as well as a relative overdosage, as systemic side effects in association with a systemic response of cGVHD were only observed in patients with low body weight. Moreover, concomitant medication involving the CYP3A pathway, crucial in the metabolism of BUD, may have led to systemic side effects as well as response. Nevertheless, it cannot be excluded that improvement in systemic manifestations reflected the natural course of cGVHD and was not a response to BUD. As patients with progressive onset of cGVHD were not treated with BUD, the results do not allow any conclusion as to the efficacy in the presence of high-risk cGVHD.
3 BUD was well tolerated without any major side effects attributable to BUD. Owing to the predominantly local effect of BUD, relapses of symptoms of cGVHD after withdrawal of BUD as well as progression of GVHD at other organ sites were observed in the majority of patients. This may indicate that BUD single-agent treatment merely 
